Indications – Kepplah http://kepplah.com/ Thu, 10 Jun 2021 10:08:37 +0000 en-US hourly 1 https://wordpress.org/?v=5.7.2 https://kepplah.com/wp-content/uploads/2021/05/kepplah-150x150.png Indications – Kepplah http://kepplah.com/ 32 32 Vulvodynia Treatment Market Research Report by Type, Indication, Supplier, Region – Global Forecast to 2026 https://kepplah.com/vulvodynia-treatment-market-research-report-by-type-indication-supplier-region-global-forecast-to-2026/ https://kepplah.com/vulvodynia-treatment-market-research-report-by-type-indication-supplier-region-global-forecast-to-2026/#respond Thu, 10 Jun 2021 08:53:00 +0000 https://kepplah.com/vulvodynia-treatment-market-research-report-by-type-indication-supplier-region-global-forecast-to-2026/

Vulvodynia Treatment Market Research Report By Type (Biofeedback & Physiotherapy, Intralesional Injections & Oral Treatment), By Indication (Generalized Vulvodynia & Localized Vulvodynia), By Vendors, By Region (Americas, Asia Pacific & Europe, Middle East and Africa) – Global Forecast to 2026 – Cumulative Impact of COVID-19

New York, June 10, 2021 (GLOBE NEWSWIRE) – Reportlinker.com Announces the Publication of the “Vulvodynia Treatment Market Research Report By Type, By Indication, By Vendor, By Region – Global Forecast To 2026 – Cumulative impact of COVID- 19 “- https://www.reportlinker.com/p06088875/?utm_source=GNW

The global vulvodynia treatment market size was estimated to be $ 42.52 billion in 2020 and is expected to reach $ 46.39 billion in 2021, at a compound annual growth rate (CAGR) of 9.43% from 2020 to 2026 to reach USD 73.04 billion by 2026.

Market Statistics:
The report provides market size and forecast in five major currencies – USD, EUR GBP, JPY and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years 2022 to 2026 are considered as the forecast period.

Market segmentation and coverage:
This research report categorizes Vulvodynia Treatment to forecast revenue and analyze trends in each of the following submarkets:

Based on type, the vulvodynia treatment market has been studied in the areas of biofeedback and physiotherapy, intralesional injections, oral treatment, surgical treatment, and topical treatment.

Based on the indication, the vulvodynia treatment market has been investigated for generalized vulvodynia and localized vulvodynia.

Based on the vendors, the Vulvodynia Treatment market has been studied in hospitals and healthcare providers, pharmaceutical and biotechnology companies, and research and development centers.

On the basis of geography, the Vulvodynia Treatment market has been studied to America, Asia-Pacific, Europe, Middle East & Africa. The Americas are further explored in Argentina, Brazil, Canada, Mexico, and the United States. Asia-Pacific is further explored in China, India, Indonesia, Japan, Malaysia, Philippines, South Korea and Thailand. Europe, Middle East and Africa are also studied in France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, Arab Emirates United and the United Kingdom.

Cumulative impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected nearly every industry, and the long-term effects are expected to impact the growth of the industry during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of the underlying issues of COVID-19 and potential pathways to follow. The report provides insight on COVID-19 considering changes in consumer behavior and demand, purchasing patterns, supply chain diversion, dynamics of current market forces, and significant government interventions . The updated study provides information, analysis, estimates and forecasts, considering the impact of COVID-19 on the market.

Competitive strategic window:
The Competitive Strategy Window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for suppliers to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to continue the expansion and growth of the business during a forecast period.

FPNV positioning matrix:
FPNV Positioning Matrix assesses and ranks vendors in the vulvodynia treatment market based on business strategy (company growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features, and customer support) that helps businesses make better decisions and better understand the competitive landscape.

Market share analysis:
The market share analysis offers the analysis of the suppliers considering their contribution to the overall market. It provides the idea of ​​its revenue generation in the overall market compared to other space providers. It provides insight into the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of the suppliers for the base year. It reveals the characteristics of the market in terms of traits of accumulation, fragmentation, dominance and fusion.

Company usability profiles:
The report deeply explores the significant recent developments of leading vendors and innovation profiles in the global Vulvodynia Treatment market including Allergan, Inc., AstraZeneca Pharmaceuticals, Cellegy Pharmaceuticals, Inc., Depomed Inc., Dipharma Francis Srl, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Lumen Therapeutics, LLC, Novartis Pharmaceuticals, Noven Pharmaceuticals, Inc., Pfizer Inc., Sanofi Aventis, Upsher-Smith Laboratories, LLC and VuVatech LLC.

The report provides information on the following pointers:
1. Market penetration: provides comprehensive information on the market offered by the major players
2. Market Development: Provides detailed information on lucrative emerging markets and analyzes penetration into mature market segments.
3. Market diversification: provides detailed information on new product launches, untapped geographies, recent developments and investments
4. Competitive Assessment and Intelligence: Provides a comprehensive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape and manufacturing capabilities of key players
5. Product Development and Innovation: Provides intelligent information on future technologies, R&D activities and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast for the global Vulvodynia Treatment market?
2. What are the inhibitory factors and impact of COVID-19 shaping the global Vulvodynia Treatment market during the forecast period?
3. What are the products / segments / applications / areas to invest in during the forecast period of the global Vulvodynia Treatment Market?
4. What is the competitive strategic window for opportunities in the global Vulvodynia Treatment market?
5. What are the technological trends and regulatory frameworks in the global Vulvodynia Treatment market?
6. What is the market share of the major vendors in the global Vulvodynia Treatment market?
7. What strategic fashions and moves are considered appropriate for entering the global Vulvodynia Treatment market?
Read the full report: https://www.reportlinker.com/p06088875/?utm_source=GNW

About Report link
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Source link

]]>
https://kepplah.com/vulvodynia-treatment-market-research-report-by-type-indication-supplier-region-global-forecast-to-2026/feed/ 0
Summary of FDA approvals: Aduhelm, Brexafemme, Tembexa https://kepplah.com/summary-of-fda-approvals-aduhelm-brexafemme-tembexa/ https://kepplah.com/summary-of-fda-approvals-aduhelm-brexafemme-tembexa/#respond Wed, 09 Jun 2021 14:18:08 +0000 https://kepplah.com/summary-of-fda-approvals-aduhelm-brexafemme-tembexa/

A weekly update on new drug approvals and indications from the United States Food and Drug Administration (FDA).

New approvals
Aduhelm approved for slowing Alzheimer’s disease by targeting motor disease process

Aduhelm (aducanumab) by Biogen received acceleration approval for the treatment of patients with Alzheimer’s disease, making it the first new treatment of the disease since 2003.

Human monoclonal antibody is also a unique therapy for disease in that it targets the underlying disease process and not the symptoms of the disease. The therapy is aimed at slowing the progression of the disease rather than reversing the process.

Aduhelm’s Fast Track Approval Was Based on the Brain Beta Amyloid Plaque Reduction Surrogate Endpoint in the Double-Blind, Randomized, Placebo-Controlled Dosing Study EMERGE, TO HIRE, and FIRST clinical trials involving a total of 3,482 patients with Alzheimer’s disease. Patients receiving study drug experienced a significant reduction in plaque depending on dose and time, while controls showed no such reduction.

The drug’s approval was marked by concerns, including from some members of the agency’s independent advisory committee who raised questions about the efficacy data. Two of the trials, EMERGE and ENGAGE were put on hold for unnecessary in 2019. Biogen later said that a re-analysis of EMERGE data showed that the trial met its primary endpoint of slowing clinical decline, and that ENGAGE data supported Emerge’s results, although this trial did not meet its primary endpoint (RELATED: FDA approves aducanumab for use in Alzheimer’s disease, Regulatory guidance June 7, 2021).

Under the fast-track approval provisions, current approval is contingent on the results of a new randomized controlled trial required to verify the clinical benefit of Aduhelm. Approval could be withdrawn if the follow-up trial fails to verify clinical benefit.

Aduhelm obtained the expedited designation.

Brexafemme Approved As One Day Oral Therapy For Vaginal Yeast Infection

Brexafemme (ibrexafungerp tablets) from Scynexis has been approved as a treatment for vulvovaginal candidiasis (CVV), also known as vaginal yeast infection, in adult women and younger postmenarchal patients.

One-day oral treatment with nonazole is the first drug approved in a new triterpenoid antifungal class for over 20 years. Its approval was based on the efficacy results of phase 3 multicenter, randomized, double-blind, placebo-controlled VANISH 303 and 306 studies in women with CVC.

Brexafemme has received Qualified Infectious Disease Product (QIDP) and Fast Track designations. Under the designation QIDP, the therapy is expected to enjoy 10 years of commercial exclusivity in the United States. The drug is also protected by multiple patents, including one for the ibrexafungerp molecule, under which it will enjoy 14 years of protection in the United States, until its expiration in 2035.

Ibrexafungerp is also in development treat Candida auris infections, including candidemia. C. auris is an emerging fungal disease that is considered a global health threat because it can cause epidemics in healthcare facilities and is often multidrug resistant.

Tembexa gets green light for smallpox treatment

Tembexa (brincidofovir) from Chimerix has been approved for the treatment of smallpox in adults and children.

The disease has been considered eradicated since 1980, but concerns remain about the use of the variola virus as a biological weapon. The therapy was developed in conjunction with the Advanced Biomedical Research and Development Authority of the US Department of Health and Human Services.

The effectiveness of Tembexa has been studied in animals infected with the virus. It was approved under the Animal rule, which allows the results of animal studies as the basis for an approval when it is not feasible or ethical to conduct trials in humans (RELATED: Smallpox antiviral approved under the FDA’s Animal Rule, Regulatory guidance June 7, 2021).

The results of the animal study showed that more animals treated with Tembexa survived infection with a smallpox virus compared to those given a placebo.

Tembexa has undergone priority review and expedited designations and orphan drugs.

Ryplazim approved as the first treatment for plasminogen deficiency in adults and children

Ryplazim from ProMetic (plasminogen, human-tmvh) has been approved as therapy for adults and children with type 1 plasminogen deficiency, also called hypoplasminogenemia.

The rare genetic disorder, for which there were no previous treatment options, is characterized by impaired normal function of tissues and organs, which can lead to blindness.

The approval of Ryplazim was based on the results of an open-label, single-arm (unblinded) clinical trial in 15 adult and pediatric patients from the indicated population who were treated with the study drug for 48 weeks. There was a 50% improvement in the 11 patients who had lesions at baseline. At 48 weeks, there were no new or recurrent lesions in any of the 15 patients.

Ryplazim has achieved orphan and fast track designations and has received a priority review and a priority review voucher for rare pediatric diseases.

New indications
Zeposia obtains expanded indication for active ulcerative colitis

Bristol Myers Squibb’s Zeposia (ozanimod) received a extended indication for the treatment of adults with moderate to severe active ulcerative colitis, a chronic inflammatory bowel disease.

Approval of the 0.92 mg dose for this indication was supported by the efficacy and safety results of two multicenter, randomized, double-blind, placebo-controlled clinical studies, study UC 1 (induction) and study UC 2 (maintenance) in the indicated population. Patients who received and responded to Zeposia in Study 1 were re-randomized to either study drug or placebo in the maintenance arm for 52 weeks, during which time they had to reduce their concomitant dose of corticosteroids. A total of 80% of patients on Zeposia and 54.6% of patients on placebo completed the study. Eligible patients were entered into an ongoing open-label extension trial to assess the long-term profile of Zeposia.

Zeposia was originally approved in 2020 for the treatment of adults with relapsing forms of multiple sclerosis.

Wegovy approved for chronic weight management

Wegovy (semaglutide injection) from Novo Nordisk obtained a extended indication for chronic weight management in adults with obesity or overweight and at least one weight-related condition, such as hypertension, type 2 diabetes or high cholesterol.

The use of the glucagon-like peptide-1 (GLP-1) receptor agonist for this indication should be combination with a reduced calorie diet and increased physical activity.

Wegovy’s approval was based on the safety and efficacy results of four trials in which over 2,600 patients received Wegovy and over 1,500 patients received placebo for up to 68 weeks. In one trial, which included patients without diabetes, those treated with Wegovy lost an average of 14.9% of their initial body weight, an absolute difference of 12.4% more than those given a placebo. In another trial, in adults with type 2 diabetes, those given Wegovy lost 6.2% more of their initial body weight than those given a placebo.

Semaglutide was first approved as Ozempic in 2017 as therapy for type 2 diabetes.

Ultomiris obtains new indication for the treatment of children with rare blood disease

Alexion’s Ultomiris (ravulizumab-cwvz injection) received extended indication for the treatment of patients 1 month or older with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease caused by genetic mutations.

The approval of Ultomiris was based on the results of a study involving 13 patients aged 9 to 17 years with PNH. Of the 13 patients, 5 had not received previous treatment with a complement inhibitor and 8 had been treated with eculizumab, a complement inhibitor approved for the treatment of PNH. After 26 weeks, 60% of previously untreated patients avoided a transfusion, and the 8 patients who had previously received eculizumab avoided a transfusion.

Ultomiris has received priority review and orphan drug designation for the indication of pediatric PNH.

It was originally approved in 2018 for the treatment of adults with PNH and in 2019 for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome.

© 2021 Society of Regulatory Affairs Professionals.


Source link

]]>
https://kepplah.com/summary-of-fda-approvals-aduhelm-brexafemme-tembexa/feed/ 0
There is no indication that Canada will withdraw its request for judicial review of human rights tribunal orders, says Cindy Blackstock https://kepplah.com/there-is-no-indication-that-canada-will-withdraw-its-request-for-judicial-review-of-human-rights-tribunal-orders-says-cindy-blackstock/ https://kepplah.com/there-is-no-indication-that-canada-will-withdraw-its-request-for-judicial-review-of-human-rights-tribunal-orders-says-cindy-blackstock/#respond Wed, 09 Jun 2021 01:16:51 +0000 https://kepplah.com/there-is-no-indication-that-canada-will-withdraw-its-request-for-judicial-review-of-human-rights-tribunal-orders-says-cindy-blackstock/

Cindy Blackstock, Executive Director of the First Nations Child and Family Caring Society, holds a press conference on Parliament Hill in Ottawa on September 15, 2016.

Sean Kilpatrick / The Canadian Press

There is no indication that Canada will withdraw its application for judicial review of two human rights tribunal orders despite a motion passed in the House of Commons on the matter on Monday, said First Nations children’s advocate Cindy Blackstock .

Ms Blackstock told The Globe and Mail that her organization, the First Nations Child and Family Caring Society of Canada, is preparing for hearings in Federal Court starting Monday.

“We will go to court and the children will win,” she said. “And when they do, the Canadiens will win too. “

The story continues under the ad

An NDP motion was passed in the House of Commons on Monday with 271 MPs from all political parties voting for, including several Liberal MPs, and 0 against. The motion included calls in Ottawa to end legal actions against Canadian Human Rights Tribunal orders regarding discrimination against Indigenous children.

Prime Minister Justin Trudeau and members of his cabinet abstained on the vote on the motion. Its adoption is considered an expression of the House but is not binding, which means that the government cannot be compelled to act. The Liberal government has faced increased political pressure on supports for First Nations children after child remains were reported at the site of the former Kamloops Indian Residential School in British Columbia.

Trudeau said on Tuesday his government was “very clear that the children or now the adults” who have suffered harm at the hands of the child welfare system deserve compensation. He also noted the adoption of a law on the child protection system and efforts to ensure that indigenous communities “remain in charge of and can protect, within the framework of their language and culture, children at risk ”.

NDP MP Charlie Angus said on Tuesday the Liberal caucus was not siding with the Prime Minister on Monday’s motion.

“It’s supposed to be his most important relationship and he skipped the vote,” Mr. Angus said. “I don’t think that gives him a free pass, then, to go back to court to continue fighting the children.” Parliament has spoken.

Ottawa has filed applications for judicial review of two orders of the Canadian Human Rights Tribunal in the Federal Court. The body was established by Parliament in 1977 and legally decides whether a person or organization has engaged in a discriminatory practice as defined by the Canadian Human Rights Act. The purpose of the law is to protect individuals from discrimination and declares that all Canadians have the right to equality, equal opportunity, fair treatment and an environment free from discrimination.

In 2019, the court found that the federal government deliberately and recklessly discriminated against Indigenous children on reserves by failing to fund child and family services. He also ordered Ottawa to provide up to $ 40,000 to First Nations children who were needlessly taken into care on or after January 1, 2006, adding that his orders also cover parents or grandparents and children. deprived of essential services.

The story continues under the ad

Ottawa said in its application for judicial review that it did not oppose the general principle that compensation for First Nations people affected by a discriminatory funding model can be provided in appropriate circumstances. But he said the government sees grounds for the claim based on its belief that the court erred in its decision, including on the order for monetary compensation to the children, parents and grandparents of the First Nations under the Canadian Human Rights Act.

A second court order relates to Jordan’s Principle, which seeks to ensure that First Nations children can access services and supports when they need them. It demands that children have access to services without delay caused by skill issues.

In 2020, the court concluded that Jordan’s Principle criteria could include a child who is registered or eligible for registration under the Indian Act, a child whose parent or guardian is registered under the Indian Act. Indian Act, a child recognized by his community for the purposes of Jordan’s Principle and a child who is ordinarily resident on a reserve.

The government also said legal questions regarding the scope of the court’s power to make these decisions are important and that it is seeking court advice.

A spokesperson for Indigenous Services Minister Marc Miller said in a statement that Ottawa had made “substantial progress” in responding to Canadian Human Rights Tribunal rulings.

“Our position regarding the September 2019 decision is that the CHRT exceeds its jurisdiction and, therefore, unilaterally imposes a one-size-fits-all solution that hinders fair compensation,” said press secretary Adrienne Vaupshas. .

The story continues under the ad

Find out what’s going on in the corridors of power with today’s top headlines and political commentaries curated by The Globe’s editors (subscribers only). register today.


Source link

]]>
https://kepplah.com/there-is-no-indication-that-canada-will-withdraw-its-request-for-judicial-review-of-human-rights-tribunal-orders-says-cindy-blackstock/feed/ 0
Otter tail stock gives all indications of fair value https://kepplah.com/otter-tail-stock-gives-all-indications-of-fair-value/ https://kepplah.com/otter-tail-stock-gives-all-indications-of-fair-value/#respond Tue, 08 Jun 2021 02:14:49 +0000 https://kepplah.com/otter-tail-stock-gives-all-indications-of-fair-value/

– By GF value

The otter tail stock (NAS: OTTR, 30-year finances) is considered to be fair valued, according to the GuruFocus value calculation. The GuruFocus Value is GuruFocus’s estimate of the fair value at which the stock is to trade. It is calculated based on the historical multiples at which the stock has traded, the company’s past growth, and analysts’ estimates of the company’s future performance. If a share’s price is significantly above the GF value line, it is overvalued and its future performance may be poor. On the other hand, if it is significantly below the GF value line, its future return is likely to be higher. At its current price of $ 48.89 per share and market cap of $ 2 billion, Otter Tail’s stock is estimated to be fair. The GF value for Otter Tail is shown in the table below.

Otter tail stock gives all <a class=indications of fair value” src=”https://s.yimg.com/ny/api/res/1.2/6wm2pbcHs2qyePIwKGuqOw–/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU3Ng–/https://s.yimg.com/uu/api/res/1.2/QIfzq3JWnCjFCuatC.Dt.w–~B/aD0zNjA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e8571e00f9858dd5376e4fa9a9668681″/>

Otter tail stock gives all indications of fair value

Because Otter Tail is fairly valued, its long-term stock return is likely to be close to the growth rate of its business, which has averaged 0.6% over the past five years.

Connect: These companies can offer higher future returns with reduced risk.

Since investing in companies with poor financial strength could result in a permanent loss of capital, investors should carefully consider the financial strength of a company before deciding whether or not to buy shares. Examining the cash-to-debt ratio and interest coverage can provide a good initial perspective on the financial strength of the business. Otter Tail has a cash to debt ratio of 0.00, which ranks in the bottom 10% of utilities – regulated companies. Based on this, GuruFocus ranks Otter Tail’s financial strength as 3 out of 10, which suggests a poor track record. Here is Otter Tail’s debt and cash flow over the past few years:

Otter tail stock gives all indications of fair value

Investing in profitable businesses carries less risk, especially in companies that have demonstrated consistent profitability over the long term. Typically, a business with high profit margins offers better performance potential than a business with low profit margins. Otter Tail has been profitable 8 years in the last 10 years. In the past 12 months, the company achieved sales of $ 917.1 million and earnings of $ 2.47 per share. Its operating margin of 16.66% in the mid-range companies in the Utilities – Regulated industry. Overall, GuruFocus rates Otter Tail’s profitability as fair. Here is Otter Tail’s revenue and bottom line for the past few years:

Otter tail stock gives all indications of fair value

Otter tail stock gives all indications of fair value

Growth is probably the most important factor in the valuation of a business. GuruFocus research has shown that growth is closely tied to the long-term performance of a company’s stocks. The faster a company grows, the more likely it is to create shareholder value, especially if the growth is profitable. The average annual growth rate of turnover over 3 years Otter Tail is 0.6%, which ranks among the average for companies in the Utilities – Regulated sector. The average growth rate of EBITDA over 3 years is 3.8%, which is in line with the average for companies in the Utilities – Regulated sector.

One can also assess a company’s profitability by comparing its return on invested capital (ROIC) to its weighted average cost of capital (WACC). Return on Invested Capital (ROIC) measures how well a business generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all of its security holders to fund its assets. If the return on invested capital exceeds the weighted average cost of capital, the company is likely to create value for its shareholders. Over the past 12 months, Otter Tail’s ROIC is 5.36 while its WACC is 3.98. Otter Tail’s historical ROIC vs WACC comparison is shown below:

Otter tail stock gives all indications of fair value

Otter tail stock gives all indications of fair value

In summary, Otter Tail (NAS: OTTR, 30 years Financials) is estimated at fair value. The company’s financial situation is bad and its profitability is fair. Its growth is in the mid-range of companies in the Utilities – Regulated industry. To learn more about Otter Tail’s stock, you can view its 30-year financial data here.

To find out about high-quality companies that can deliver above-average returns, please see GuruFocus High Quality Low Capex Screener.

This article first appeared on GuruFocus.


Source link

]]>
https://kepplah.com/otter-tail-stock-gives-all-indications-of-fair-value/feed/ 0
Robinson’s suspension hint on what the future holds for the social media generation: Ashwin https://kepplah.com/robinsons-suspension-hint-on-what-the-future-holds-for-the-social-media-generation-ashwin/ https://kepplah.com/robinsons-suspension-hint-on-what-the-future-holds-for-the-social-media-generation-ashwin/#respond Mon, 07 Jun 2021 09:49:39 +0000 https://kepplah.com/robinsons-suspension-hint-on-what-the-future-holds-for-the-social-media-generation-ashwin/

Senior Indian spinner R Ashwin is sorry for England leader Ollie Robinson, who was suspended for racist and sexist tweets published in 2012, and called his punishment “a strong indication of what the future holds for this. social media generation “. Robinson, who made his England debut in the first test against New Zealand which ended in a draw on Sunday, has been suspended from international cricket pending an investigation after his tweets, which were then published that he was a teenager resurfaced on the opening day of the game at Lord East in London.

“I can understand the negative feelings towards what #OllieRobinson did years ago, but I’m so sorry he’s been suspended after an impressive start to his testing career,” Ashwin said on his Twitter account.

“This suspension is a strong indication of what the future holds for this social media general. Robinson won seven wickets in the game and also touched 42 in England’s opening innings.

But he won’t be available for selection for the second test from Edgbaston on Thursday. He will immediately leave the England camp and return to his county, Sussex.

The 27-year-old apologized on Wednesday, admitting to posting “racist and sexist tweets” as a teenager. He had expressed “deep regret” about his actions while declaring “I am not racist and I am not sexist”. Former India Test opener Wasim Jaffer responded to Ashwin’s tweet with a cheeky message.

“I’m just glad I found Twitter after I retired,” Jaffer tweeted.

Batting coach Graham Thorpe has said that in the future England may start reviewing the social media history of players ahead of their selection to the national team.

Robinson’s offensive tweets targeted Muslims and Asians and he said he was “ashamed” of them.

Screenshots of his posts resurfaced on numerous social media platforms after the lunch break on Day 1 of the first test between England and New Zealand at Lord’s.

(This story was not edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


Source link

]]>
https://kepplah.com/robinsons-suspension-hint-on-what-the-future-holds-for-the-social-media-generation-ashwin/feed/ 0
June 21 ‘only in pencil’ unlock date – Matt Hancock gives clearest indication yet that roadmap is being delayed https://kepplah.com/june-21-only-in-pencil-unlock-date-matt-hancock-gives-clearest-indication-yet-that-roadmap-is-being-delayed/ https://kepplah.com/june-21-only-in-pencil-unlock-date-matt-hancock-gives-clearest-indication-yet-that-roadmap-is-being-delayed/#respond Sun, 06 Jun 2021 14:20:01 +0000 https://kepplah.com/june-21-only-in-pencil-unlock-date-matt-hancock-gives-clearest-indication-yet-that-roadmap-is-being-delayed/

Health Secretary Matt Hancock during his appearance on the BBC1 news program, The Andrew Marr Show.  Photo date: Sunday, June 6, 2021.

Health Secretary Matt Hancock during his appearance on the BBC1 news program, The Andrew Marr Show. Photo date: Sunday, June 6, 2021.

Matt Hancock, in what will be considered the clearest indication to date that the target date for the lifting of all restrictions could slip, pointed out that June 21 was a “not before” date and that it was not. ‘was only “listed” as the next stage of containment.

The senior government minister also hinted that social distancing may continue beyond the final stage of the prime minister’s roadmap.

The comments come as Covid-19 cases continued to rise in the UK amid reports Boris Johnson plans to delay so-called Freedom Day by at least two weeks in order to allow more of people to be fully vaccinated against the Indian variant.

Register now to our daily newsletter

The newsletter i cut through the noise

The Health Secretary, asked if the removal of restrictions on June 21 could be postponed if the data for the Indian variant “got bad”, told the BBC’s Andrew Marr Show: “We are absolutely open to doing so if that’s what has to happen.

“We said in the roadmap that June 21 is the date we will not go to step 4 before then and we will look at the data.

“This is exactly what we are doing, so the roadmap has been put in place to be able to accommodate these kinds of changes. “

It has been reported that revisions to the roadmap could cause the government to backtrack to encourage a return to the workplace, while social distancing in bars and restaurants should remain, along with limits on audience in theaters and cinemas.

Mr Hancock admitted that the emergence of the Indian variant, which has become dominant in the UK, made the ‘math’ about whether to proceed with the unlock this month ‘more difficult’ as he revealed that the latter Scientific advice is that the mutation – also known as the Delta variant – is 40% more transmissible than the Kent strain.

The Health Secretary, with a decision on easing the lockdown expected next week, said he would not “rule out” measures such as wearing face coverings in public places and working from home if possible continuing long term.

“The way we look at it is that Step 4 involves removing the remaining social restrictions like the rule of six and some of the business closures that are still there,” he said on the show.

“And separately, we have work on what the social distancing rules should be after that. “

In a separate interview with Sky News’ Trevor Phillips On Sunday program, Mr Hancock said the government “has yet to define the approach to social distancing after Stage 4” and that plans are currently underway. development course with scientific advisers on how to proceed. without issue.

Labor has indicated they may support some restrictions that remain in place as long as they are corroborated by evidence.

Shadow Education Secretary Kate Green told Sky News: “I would say if we are to maintain some safeguards beyond June 21, this is what the government should be doing, but I think ‘it’s really important that this is a decision made on the basis of the data. “

Hancock said he expected “about three-fifths” of all adults to be fully vaccinated within the next fortnight, with 52% currently double-injected, as indicators suggest the vaccines are helping to sever the link between the increase in cases and an increase in hospital admissions.

Former Prime Minister and Labor leader Tony Blair argued that those who received both injections should be given additional freedoms to get people to accept the offer of vaccination.

“I think since everyone will be able to get vaccinated except those who cannot for medical reasons, I think it is really important that people are encouraged to get vaccinated”, a- he told the Andrew Marr Show.

The campaign to roll out vaccines for every adult by the end of July continues at a steady pace as the Health Secretary announced that those under 30 will be asked to reserve for their first dose this week.

The vaccination campaign comes amid growing fears that the Indian variant is fueling an increase in the number of cases across Britain.

Of the 12,431 cases of Indian variants confirmed to date in the UK, 10,797 are in England, 1,511 in Scotland, 97 in Wales and 26 in Northern Ireland.

The UK on Friday recorded its highest number of new confirmed coronavirus cases – 6,238 – since the end of March, according to official figures, although the number on Saturday fell slightly to 5,765 laboratory-confirmed cases.

Dame Anne Johnson, professor of infectious disease epidemiology at University College London (UCL), said reopening would be a “very finely-judged decision” and society will have to learn to live with the coronavirus.

Describing the data coming in this week as “absolutely critical,” the president of the Academy of Medical Sciences told Trevor Phillips on Sunday: “We certainly don’t want to continue delaying indefinitely. It will be a very finely judged decision when we see these. results. “


Source link

]]>
https://kepplah.com/june-21-only-in-pencil-unlock-date-matt-hancock-gives-clearest-indication-yet-that-roadmap-is-being-delayed/feed/ 0
The Dril-Quip stock gives it all https://kepplah.com/the-dril-quip-stock-gives-it-all/ https://kepplah.com/the-dril-quip-stock-gives-it-all/#respond Sat, 05 Jun 2021 23:04:07 +0000 https://kepplah.com/the-dril-quip-stock-gives-it-all/

The stock of Dril-Quip (NYSE: DRQ, 30-year Financials) is considered to be fairly valued, as calculated by GuruFocus Value. The GuruFocus Value is GuruFocus’s estimate of the fair value at which the stock is to trade. It is calculated based on the historical multiples at which the stock has traded, the company’s past growth, and analysts’ estimates of the company’s future performance. If a share’s price is significantly above the GF value line, it is overvalued and its future performance may be poor. On the other hand, if it is significantly below the GF value line, its future return is likely to be higher. At its current price of $ 38.24 per share and market cap of $ 1.4 billion, Dril-Quip stock gives all indications of its fair value. The GF value for Dril-Quip is shown in the table below.

Since Dril-Quip is valued at its fair value, the long-term return on its stock will likely be close to the growth rate of its business.

Link: These companies can offer higher future returns with reduced risk.

Companies with poor financial strength present investors with a high risk of permanent capital loss. To avoid a permanent loss of capital, an investor should do his research and consider the financial strength of a company before deciding to buy stocks. A company’s cash-to-debt ratio and interest coverage are both a great way to understand its financial strength. Dril-Quip has a cash-to-debt ratio of 63.50, which ranks better than 84% of companies in the oil and gas industry. The overall financial strength of Dril-Quip is 7 out of 10, which indicates that the financial strength of Dril-Quip is fair. Here is Dril-Quip’s debt and cash flow over the past few years:

https://www.gurufocus.com/news/1447099/-1

It is less risky to invest in profitable companies, especially those whose profitability is constant over the long term. A business with high profit margins is generally a safer investment than one with low profit margins. Dril-Quip has been profitable 7 in the last 10 years. In the past twelve months, the company achieved sales of $ 350.2 million and a loss of $ 1.28 per share. Its operating margin is -6.35%, which puts it in the middle of the companies in the oil and gas industry. Overall, Dril-Quip’s profitability is ranked 6 out of 10, indicating acceptable profitability. Here is Dril-Quip’s sales and net income over the past few years:

https://www.gurufocus.com/news/1447099/-1

Growth is probably one of the most important factors in the valuation of a business. GuruFocus research has shown that growth is closely tied to the long-term performance of a company’s stocks. If a company’s business is growing, the business typically creates value for its shareholders, especially if the growth is profitable. Likewise, if the income and profits of a business decrease, the value of the business will decrease. Dril-Quip’s 3-year average revenue growth rate is within the average for companies in the oil and gas industry. Dril-Quip’s 3-year average EBITDA growth rate is -7.8%, which is in line with the average for companies in the oil and gas industry.

Another way to look at the profitability of a business is to compare its return on invested capital and the weighted cost of capital. Return on Invested Capital (ROIC) measures the extent to which a business generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company should pay on average to all its security holders to finance its assets. We want to have a return on invested capital greater than the weighted cost of capital. Over the past 12 months, Dril-Quip’s return on invested capital is -2.69 and its cost of capital is 9.93. Dril-Quip’s historical ROIC vs WACC comparison is shown below:

1401313433101553664.png

In short, Dril-Quip’s stock (NYSE: DRQ, 30-year-old Financials) gives every indication of being fair valued. The company’s financial position is fair and its profitability is fair. Its growth is in the mid-range of companies in the oil and gas industry. To find out more about the Dril-Quip share, you can consult its financial data over 30 years here.

To find out about high-quality companies that can deliver above-average returns, please see GuruFocus High Quality Low Capex Screener.


Source link

]]>
https://kepplah.com/the-dril-quip-stock-gives-it-all/feed/ 0
Alphabet Stock gives all indications of being considerably overvalued https://kepplah.com/alphabet-stock-gives-all-indications-of-being-considerably-overvalued/ https://kepplah.com/alphabet-stock-gives-all-indications-of-being-considerably-overvalued/#respond Sat, 05 Jun 2021 05:00:48 +0000 https://kepplah.com/alphabet-stock-gives-all-indications-of-being-considerably-overvalued/

– By GF value

Alphabet’s stock (NAS: GOOGL, 30-year finances) shows all signs of significant overvaluation, according to the GuruFocus value calculation. The GuruFocus Value is GuruFocus’s estimate of the fair value at which the stock is to trade. It is calculated based on the historical multiples at which the stock has traded, the company’s past growth, and analysts’ estimates of the company’s future performance. If a share’s price is significantly above the GF value line, it is overvalued and its future performance may be poor. On the other hand, if it is significantly below the GF value line, its future return is likely to be higher. At its current price of $ 2,393.57 per share and market cap of $ 1,622.9 billion, Alphabet stock is showing all signs of significant overvaluation. The GF value for the alphabet is shown in the table below.

Alphabet Stock gives all <a class=indications of being considerably overvalued” src=”https://s.yimg.com/ny/api/res/1.2/25d6Rtp2ZyZV098yn6gJBg–/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU3Ng–/https://s.yimg.com/uu/api/res/1.2/2SE9NY1OTB7HH8ZxFY7RUQ–~B/aD0zNjA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/988c86acfb1a591afb1edd47e9b0d434″/>

Alphabet Stock gives all indications of being considerably overvalued

Given that Alphabet is significantly overvalued, its long-term stock return is likely to be much lower than its future business growth, which has averaged 16.5% over the past three years and is expected to grow 15.5%. , 39% per year over the next three to five years.

Connect: These companies can offer higher future returns with reduced risk.

Since investing in companies with poor financial strength could result in a permanent loss of capital, investors should carefully consider the financial strength of a company before deciding whether or not to buy shares. Examining the cash-to-debt ratio and interest coverage can provide a good initial perspective on the financial strength of the business. The alphabet has a cash-to-debt ratio of 4.98, which ranks in the average for companies in the interactive media industry. On this basis, GuruFocus ranks Alphabet’s financial strength as 8 out of 10, which suggests a strong balance sheet. Here is Alphabet’s debt and cash flow over the past few years:

Alphabet Stock gives all indications of being considerably overvalued

It is less risky to invest in profitable companies, especially those whose profitability is constant over the long term. A business with high profit margins is generally a safer investment than one with low profit margins. Alphabet has been profitable 10 in the past 10 years. In the past twelve months, the company achieved sales of $ 196.7 billion and earnings of $ 75.12 per share. His the operating margin is 25.26%, which ranks better than 82% of companies in the interactive media industry. Overall, Alphabet’s profitability is ranked 9 out of 10, indicating strong profitability. Here is Alphabet’s sales and net profit over the past few years:

Alphabet Stock gives all indications of being considerably overvalued

Alphabet Stock gives all indications of being considerably overvalued

Growth is probably one of the most important factors in the valuation of a business. GuruFocus research has shown that growth is closely tied to the long-term performance of a company’s stocks. If a company’s business is growing, the business typically creates value for its shareholders, especially if the growth is profitable. Likewise, if the income and profits of a business decrease, the value of the business will decrease. Alphabet’s 3-year average revenue growth rate is within the average for companies in the interactive media industry. Alphabet’s 3-year average EBITDA growth rate is 20.2%, which is in line with the average for companies in the interactive media industry.

A company’s profitability can also be assessed by comparing its return on invested capital (ROIC) to its weighted average cost of capital (WACC). Return on Invested Capital (ROIC) measures the extent to which a business generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company should pay on average to all of its security holders to finance its assets. If the return on invested capital exceeds the weighted average cost of capital, the company is likely to create value for its shareholders. Over the past 12 months, Alphabet’s ROIC is 25.87 while its WACC is 7.30. Alphabet’s historical ROIC vs WACC comparison is shown below:

Alphabet Stock gives all indications of being considerably overvalued

Alphabet Stock gives all indications of being considerably overvalued

In conclusion, the Alphabet stock (NAS: GOOGL, 30-year-old Financials) is believed to be significantly overvalued. The company’s financial position is solid and its profitability is solid. Its growth is in the mid-range of companies in the interactive media industry. To find out more about the Alphabet share, you can view its 30-year financial data here.

To find out about high-quality companies that can deliver above-average returns, please see GuruFocus High Quality Low Capex Screener.

This article first appeared on GuruFocus.


Source link

]]>
https://kepplah.com/alphabet-stock-gives-all-indications-of-being-considerably-overvalued/feed/ 0
Stock of applied materials gives – GuruFocus.com https://kepplah.com/stock-of-applied-materials-gives-gurufocus-com/ https://kepplah.com/stock-of-applied-materials-gives-gurufocus-com/#respond Fri, 04 Jun 2021 18:04:19 +0000 https://kepplah.com/stock-of-applied-materials-gives-gurufocus-com/

According to the GuruFocus value calculation, the inventory of applied materials (NAS: AMAT, 30-year financial data) would be significantly overvalued. The GuruFocus Value is GuruFocus’s estimate of the fair value at which the stock is to trade. It is calculated based on the historical multiples at which the stock has traded, the company’s past growth, and analysts’ estimates of the company’s future performance. If a share’s price is significantly above the GF value line, it is overvalued and its future performance may be poor. On the other hand, if it is significantly below the GF value line, its future return is likely to be higher. At its current price of $ 139.595 per share and market cap of $ 127.6 billion, Applied Materials stock is estimated to be significantly overvalued. The GF value for the applied materials is shown in the table below.

Given that Applied Materials is significantly overvalued, its long-term stock return is likely to be much lower than the future growth of its business, which has averaged 11.2% over the past three years and is expected to grow 12.2%. , 32% per year over the next three to five years. years.

Link: These companies can offer higher future returns with reduced risk.

Investing in companies with low financial strength presents a higher risk of permanent loss of capital. Thus, it is important to carefully consider the financial strength of a company before deciding whether or not to buy its shares. Looking at the cash-to-debt ratio and interest coverage is a great starting point for understanding the financial strength of a business. Applied Materials has a cash-to-debt ratio of 1.19, which is around the average for companies in the semiconductor industry. GuruFocus ranks the overall financial strength of Applied Materials at 7 out of 10, which indicates that the financial strength of Applied Materials is fair. Here is Applied Materials’ debt and cash flow over the past several years:

1400875161846042624.png

Companies that have historically been profitable over the long term pose less risk to investors who want to buy stocks. Higher profit margins usually dictate a better investment compared to a business with lower profit margins. Applied Materials has been profitable 10 in the past 10 years. In the past twelve months, the company had revenue of $ 19.8 billion and profit of $ 4.79 per share. His the operating margin is 28.07%, which ranks better than 92% of companies in the semiconductor industry. Overall, Applied Materials’ profitability is ranked 9 out of 10, indicating strong profitability. Here is Applied Materials sales and net income for the past few years:

1400875163490209792.png

Growth is probably the most important factor in the valuation of a business. GuruFocus research has shown that growth is closely tied to the long-term performance of a company’s stocks. The faster a company grows, the more likely it is to create shareholder value, especially if the growth is profitable. Applied Materials’ 3-year average annual revenue growth rate is 11.2%, which ranks better than 72% of companies in the semiconductor industry. The 3-year average EBITDA growth rate is 8.3%, which is in line with the average for companies in the semiconductor industry.

Another way to determine a company’s profitability is to compare its return on invested capital to the weighted average cost of capital. Return on invested capital (ROIC) The extent to which a business generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company should pay on average to all of its security holders to finance its assets. When the ROIC is higher than the WACC, it implies that the company creates value for the shareholders. Over the past 12 months, Applied Materials’ return on invested capital is 33.47 and its cost of capital is 10.34. The historical ROIC vs WACC comparison of applied materials is shown below:

1400875165218263040.png

In short, the stock of applied materials (NAS: AMAT, 30 years financial) gives all indications of being considerably overvalued. The company’s financial position is fair and its profitability is solid. Its growth is in the mid-range of companies in the semiconductor industry. To learn more about the Applied Materials inventory, you can view its 30-year financial data here.

To find out about high-quality companies that can deliver above-average returns, please see GuruFocus High Quality Low Capex Screener.


Source link

]]>
https://kepplah.com/stock-of-applied-materials-gives-gurufocus-com/feed/ 0
Speaker cites extended indications for dual mobility hip joints https://kepplah.com/speaker-cites-extended-indications-for-dual-mobility-hip-joints/ https://kepplah.com/speaker-cites-extended-indications-for-dual-mobility-hip-joints/#respond Thu, 03 Jun 2021 15:20:12 +0000 https://kepplah.com/speaker-cites-extended-indications-for-dual-mobility-hip-joints/

Source:

Peters CL. Indications for a double mobility joint. Featured at: Orthopedics Today Hawaii 2021; May 30-June 3, 2021; Wailea, Hawaii.

Disclosures: Peters does not report any relevant financial information.


We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact customerservice@slakinc.com.

WAILEA, Hawaii – Despite some concerns he has, a presenter at Orthopedics Today Hawaii recommended dual mobility total hip replacement for its ability to reduce hip dislocation in some high-risk primary and revision THA patients. .

Christopher L. Peters, MD, Said, in general, dual mobility and tripolar THR joints are gaining popularity.

“Built with dual mobility in the primaries and revisions [are] very effective in reducing dislocation. Now there are concerns, ”he said.

Christophe L. Peters

Christophe L. Peters

Although generally in favor of dual mobility THR systems when properly indicated, Peters cited case reports and reported “extremely low” rates in the literature that he found to be “acceptable” for sleeve misalignment, intraprosthetic dislocation, corrosion and potential ion release with these joints.

“I think the evidence for their effectiveness far outweighs any small concerns about the ion issues at this point and so, I think [the systems are] highly recommended for high risk primary dislocation patient and high risk revision patient, ”he said.

The indications for dual mobility PTH primary prostheses are patients at high risk of dislocation, with neuromuscular or connective tissue disorders, or with stiffness of the spine.

Patients with small anatomy are also indicated for dual mobility THA, such as women who require a cup size less than 50mm ”and our poly options are limited to 28 [mm] or 32 [mm] in these 40-[mm] to 48mm sockets, ”said Peters.

“Conversely, great anatomy – when you are size 60 [mm] and above the cups – when using a 36 [mm] or lower joint – we have a lot of dead space, and it is beneficial to potentially keep a femoral design closer to the patient’s femoral head, ”he said.

According to Peters, additional indications include patients with a femoral neck fracture operated posteriorly and patients undergoing conversion after previous hip surgery.

Regarding the dual mobility builds for the THR overhaul, Peters said: “Any overhaul, I think, now becomes a relative indication for using dual mobility. Fracture case, periprosthetic fracture case, secondary [periprosthetic joint infection] The PJI cases, when we come back to the second stage, I think that’s a good indication, and some cases of abductor deficiency, if our implants are in the right position, I think these are good indications for double mobility.


Source link

]]>
https://kepplah.com/speaker-cites-extended-indications-for-dual-mobility-hip-joints/feed/ 0